Kyorin Pharmaceutical Announces Signing of Acquisition Agreement of ActivX Biosciences
December 1, 2004
Kyorin Pharmaceutical Co., Ltd. (Tokyo; President: Ikuo Ogihara) ("Kyorin") agreed on December 1, 2004 with ActivX Biosciences, Inc. (California; C.E.O.: James A. Schoeneck) ("ActivX") that Kyorin will acquire ActivX. Upon the closing of the transaction, a U.S. subsidiary of Kyorin established to effectuate the acquisition will be merged with and into ActivX, and ActivX will survive the merger as a wholly owned subsidiary of Kyorin.
The aggregate price for the acquisition of ActivX is $21,000,000, and Kyorin forecasts that the economic impact on its 2004 fiscal year financial statements will be minimal.
Adobe Reader software is required to view and print PDF files. The latest version of Adobe Reader can be downloaded by accessing the Adobe Systems Incorporated website.